Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers

NCT ID: NCT04666766

Last Updated: 2023-01-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-01

Study Completion Date

2026-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate if traumatic intracranial hemorrhage can be safely ruled out by using a microwave scanner (MD100) in conjunction with a combination of different brain biomarkers analyzed in serum.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, open, multicentre trial that will enrol patients presenting to the Emergency Department (ED) because of isolated head trauma or head trauma as part of a multi trauma. Microwave scanning characteristics and biomarkers in patients with traumatic intracranial haemorrhage (TICH) (Group A) will be compared to patients with head trauma that do not have TICH (Group B). All adult patients with trauma to the head will be eligible for inclusion if a medical professional has evaluated the risk of spine injury. After additional physical examination, control of inclusion- and exclusion criteria and after informed consent has been acquired, the microwave measurement and blood sampling will be performed. Before enrolment in the study, and in the acute phase, one of the investigators or a member of the investigator staff must explain verbally the implications of study participation to the patient, and the patient is asked to give a verbal consent. As soon as is practically possible after the acute phase of the disease, the patient will sign and personally date the informed consent form. In cases where the patient is not capable to read and/or sign the informed consent, due to disability, an independent witness shall be present throughout the process of reading the written informed consent and any other information aloud and explained to the prospective patient. As an independent witness, healthcare professionals who are not responsible or in any way involved in the patient's care or treatment are accepted. The independent witness can sign on the behalf of the patient in the presence of the patient and the Investigator. More details of the informed consent procedure are described in this Clinical Investigation Plan, section 6.3.

The microwave measurement will take less than five minutes (the duration of the actual measurement is about 1,5 min and will not interfere with the patient's standard of care). The Research Nurse or the Investigator documents all patient clinical trial information in the eCRF.

Safety and usability will be evaluated throughout the trial, and a safety follow-up will be performed by the Research Nurse or Investigator approximately 24 hours after the measurement procedure.

During the data processing phase of study, the result of the microwave measurement will be compared to the result of the biomarkers, CT examination and the patient's final diagnosis. As a control group, approximately 50 demographically matched healthy volunteers (Group C) will be asked to participate in the trial. The trial will provide knowledge of the predictive value of microwave measurement and biomarkers for the diagnosis of intracranial haemorrhages in the acute TBI phase.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Injuries, Traumatic Biomarkers Microwave Imaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Caregivers
No results of the biomarker assays or microwave scans will be visible to the care givers or the participants.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Traumatic intracranial hemorrhage

Patients with traumatic intracranial hemorrhage diagnosed by Computerized Tomography of the head

Group Type ACTIVE_COMPARATOR

Microwave scanning of the head

Intervention Type DEVICE

A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.

Trauma without traumatic intracranial hemorrhage

Patients with trauma to the head but traumatic intracranial hemorrhage ruled out by Computerized tomography of the head

Group Type ACTIVE_COMPARATOR

Microwave scanning of the head

Intervention Type DEVICE

A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.

Healthy age-matched volunteers

Healthy age-matched volunteers with no previous trauma to the head within the past two weeks.

Group Type ACTIVE_COMPARATOR

Microwave scanning of the head

Intervention Type DEVICE

A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Microwave scanning of the head

A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Assay of 9 different brain biomarkers

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Verbal Informed Consent in the acute phase.
* Signed Informed Consent Form after the acute phase. On behalf of the patient, independent witness signed informed consent (in cases where the patient is unable to sign).
* Acute trauma patient with suspected head injury
* Time from injury to measurement procedure not longer than 8 hours 15 min
* Head CT prescribed by treating physician
* Patient is ≥ 18 years of age
* Patient is deemed clinically stable


* Patient is ≥ 18 years of age
* Signed informed consent

Exclusion Criteria

* Patient has suspected cervical spine fracture, per the Investigator's judgement
* Patient has by CT confirmed cervical spine fracture
* Patient has confirmed skull fracture with risk for dislocation.
* Patient has a shunt or other foreign object implanted intracranially (if known by medical records)
* Patient has agraffes or other metal parts, thick bandage (\>1cm), or other foreign materials attached to the head that are deemed to interfere with the diagnostic procedure.
* Patient diagnosed with a condition associated with risk of poor protocol compliance
* The measurement procedure is deemed to interfere with the standard of care
* Other condition or symptoms preventing the patient from entering the trial, per the investigator´s judgment


• Previous stroke or other diagnosed and/or treated brain injury
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medfield Diagnostics

INDUSTRY

Sponsor Role collaborator

Region Skane

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tomas J Vedin, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Region Skåne and Lund University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Helsingborg General Hospital

Helsingborg, Skåne County, Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tomas J Vedin, MD, PhD

Role: CONTACT

+464263131

Jacob Lundager Foberg, MD, PhD

Role: CONTACT

+464261000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jakob Lundager Forberg, MD, PhD

Role: primary

0424061000

References

Explore related publications, articles, or registry entries linked to this study.

Vedin T, Bergenfeldt H, Holmstrom E, Lundager-Forberg J, Edelhamre M. Microwave scan and brain biomarkers to rule out intracranial hemorrhage: study protocol of a planned prospective study (MBI01). Eur J Trauma Emerg Surg. 2022 Apr;48(2):1335-1342. doi: 10.1007/s00068-021-01671-7. Epub 2021 May 4.

Reference Type DERIVED
PMID: 33944977 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MBI01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.